BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36902771)

  • 1. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.
    Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P
    J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study.
    Haeuser L; Marchese M; Cone EB; Noldus J; Bayliss G; Kilbridge KL; Trinh QD
    Nephrol Dial Transplant; 2022 Jun; 37(7):1310-1316. PubMed ID: 34028534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
    Rajapakse P; Andanamala H
    World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
    Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
    BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
    Guo Q; Gao J; Guo H; Xie J; Cheng J
    Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
    JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
    Sadaat M; Jang S
    J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wu X
    J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database.
    Ruggiero R; Fraenza F; Scavone C; di Mauro G; Piscitelli R; Mascolo A; Ferrajolo C; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Pharmacol; 2020; 11():830. PubMed ID: 32581796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study.
    Bastin M; Allouchery M; Sassier M; Rouby F; Eftekhari P; Lebrun-Vignes B; Andreelli F; Bihan K
    Therapie; 2021; 76(6):695-703. PubMed ID: 33836905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
    Liu LL; Skribek M; Harmenberg U; Gerling M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review.
    Nguyen LS; Raia L; Lebrun-Vignes B; Salem JE
    Front Pharmacol; 2020; 11():619649. PubMed ID: 33613286
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
    Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
    Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
    Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
    Ma Z; Pei J; Sun X; Liu L; Lu W; Guo Q; Lyu J; Liu Y; Zhang Y; Zhao Z
    Front Pharmacol; 2021; 12():663088. PubMed ID: 34276364
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.
    Palassin P; Maria ATJ; Ladhari C; Quantin X; Montani D; Bourdin A; Boissin C; Fesler P; Hillaire-Buys D; Guilpain P; Faillie JL
    Cancer Immunol Immunother; 2022 Dec; 71(12):3093-3097. PubMed ID: 35616698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.